Neovacs announced the results of its IFN-K-001 clinical study in lupus that showed that Kinoid treatment reduces the gene dysregulation associated with the overexpression of IFN?.
Evolva has received regulatory clearance to progress its pharmaceutical compound EV-077 into Phase 2a clinical studies for the treatment of complications of diabetes.
Sunovion Pharmaceuticals Inc. announced results from a Phase 3 clinical study of ciclesonide nasal aerosol, intended for the treatment of allergic rhinitis.
Researchers studying the nature of crowds playing Foldit called some strategies “shocking” in how well they mimicked some of the methods already used by protein scientists.
Heptares Therapeutics has appointed Daniel Grau to president.
By irradiating polystyrene lab plates with ultraviolet waves, Whitehead Institute and Massachusetts Institute of Technology scientists have created a surface capable of tripling the number of human embryonic stem and induced pluripotent stem cells that can be grown in culture by current methods.
Beckman Coulter Inc. offers Biomek P1000 Span-8 pipette tips for the Biomek NXP and FXP laboratory automation workstations, which allow users to inspect aspirated volumes.
CILS International’s CILS-8200S solvent-resistant surface coating ensures variable data remains clear and legible when exposed to methanol, ethanol, acetone, IPA and THF.
The Purair 5 Ductless Fume Hoods from Air Science USA are available in 24 in, 36 in or 48 in models.
Thermo Fisher Scientific Inc.’s Nunc Roller Bottles are designed for cell culture applications in the production of vaccines and monoclonal antibody-based biopharmaceuticals.
Pall Corporation introduced the Pall Acrodisc MS Syringe Filter the first syringe filter certified for low extractables in high-performance liquid chromatography/mass spectrometry applications.
The Optima X Series preparative ultracentrifuges from Beckman Coulter, Inc. incorporate an array of contemporary technical features to enhance the user experience, increase productivity, and reduce costs.
Freeslate, Inc. announced that LEO Pharma has selected Freeslate’s Core Module 3 high-throughput research platform for evaluating solubility of drugs in various viscous formulations and for preparing samples for characterization and analysis.
MAP Pharmaceuticals Inc. said that it made a profit in the third quarter after receiving two payments from its partner, Allergan Inc. MAP said it earned $11.2 million, or 35 cents per share, and it reported $23.9 million in revenue.
Abbott announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with Humira on disease activity, including spinal mobility in patients with active ankylosing spondylitis.